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Abstract 
Neuroblastoma (NB) rarely occurs in adults, and less than 10% of the cases occur in 
patients older than 10 years. Currently, there are no standard treatment guidelines for 
adult NB patients. We report the case of a young man suffering from NB in adulthood 
with multiple recurrences. Treatment included multiple resections, chemotherapy, and 
radiotherapy. This patient remains free of clinical disease more than 7 years after 
diagnosis. 
 
Introduction 
Neuroblastoma (NB) is a tumor derived from the neural crest that usually originates in 
the adrenal medulla, but it may arise anywhere within the sympathetic nervous system. 
NB is a common malignancy in children but rarely occurs in adults; less than 10% of all 
cases are diagnosed after the age of 10 years. The incidence for patients between 30 and 39 
years of age is approximately 0.2 cases per million person-years [1, 2]. NB has different 
biological features in adolescents and adults, and a longer course in both of these groups 
than in children. However, the outcome is poor regardless of stage [3]. 
We report the effective use of multimodal therapy to achieve long-term survival in 
adult retroperitoneal NB with multiple recurrences.  
Case Report 
In February 2002, a previously healthy 25-year-old man presented with a supraclavicular left node 
that was completely resected with a diagnosis of neurofibrosarcoma. Physical examination revealed an 
abdominal mass. Computed tomography (CT) showed a multinodular 13.5 × 10-cm tumor in the  
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retroperitoneal region, covering the aorta and repulsing the inferior vena cava. No distant metastases 
were detected. Guided needle biopsy of the lesion revealed adult NB upon histopathological 
examination at an outside institution. Histologically, the tumor consisted of small and round-shaped 
pseudorosette-forming cells with hyperchromatic nuclei. Immunohistochemistry showed cytoplasmic 
positivity for neuronal specific enolase (NSE), chromogranin A, and synaptophysin. A bone scan was 
negative. Metaiodobenzylguanidine (MIBG) scintigraphy demonstrated an increased uptake by the 
mass described above. The serum levels of NSE and catecholamine metabolites, including dopamine, 
were in the normal range. Catecholamine metabolites were not increased in a 24-hour urine collection. 
The patient was diagnosed as having stage IV NB. Combination chemotherapy with a CADO/ 
CDDP-VP16 regimen according to the pediatric protocol was started with cyclophosphamide (CPM 
1,500 mg/m
2 per cycle), doxorubicin (AD 60 mg/m
2 per cycle), vincristine (2 mg per cycle), cisplatin 
(CDDP 100 mg/m
2 per cycle), and etoposide (VP16 500 mg/m
2 per cycle) with G-CSF. 
After 5 courses of chemotherapy, the mass was surgically removed and a lomboaortic 
lymphadenectomy performed. The mass was NB with 70% necrosis. Fluorescence in situ hybridization 
analysis of the MYCN locus showed no MYCN oncogene amplification. External irradiation of para-
aortic lymph nodes was performed postoperatively, delivering 35 Gray (Gy) with 1.8 Gy per day, 5 days 
per week.  
Postoperative MIBG scintigraphy showed no abnormal uptake. 
Semestrial follow-up studies, including MIBG scintigraphy, CT, and catecholamine values in the 
urine and blood were performed. 
The first recurrence occurred in 2005, 30 months after the initial surgery. The patient was 
asymptomatic when he presented for the visit. Physical examination and routine blood levels were 
normal, but the serum dopamine level was elevated (655 μg/g creatinine for normal range 96–463). 
MIBG scintigraphy demonstrated an increased uptake in the upper mediastinal region, and CT scans of 
the chest revealed a 25-mm mediastinal mass. The patient underwent thoracotomy and the mass 
measuring 40 × 60 mm was removed completely. Histological and immunohistochemical examination 
confirmed the diagnosis of NB metastasis. 
One month later, the postoperative scintigraphy showed abnormal uptake in the left supraclavicular 
area, corresponding to a metastatic lymph node. Because MIBG scintigraphy confirmed disease 
progression, we administrated carboplatin/VP16 (carboplatin 800 mg/m
2 per cycle and VP16 500 
mg/m
2 per cycle with G-CSF) therapy. After 2 courses of chemotherapy, 
18FDG scintigraphy showed a 
partial response with a diminishing SUVmax from 5.2 to 3.3. A 3rd surgical resection was performed, 
guided by a perioperative detection probe 24 h after the injection of 5.2 mCi of iodine-123-labeled 
MIBG. 
Postoperative metabolic imaging performed at 1, 3, 6, 12, 15, 21, and 24 months did not reveal any 
abnormality in connection with the disease. However, the postoperative FDG-TEP in the 15th month 
showed an increased uptake in the left popliteal area, corresponding to a less than 1-cm nodule localized 
in the lateral part of the superior extremity of the left leg. Surgical biopsy revealed a hemangioma with 
schwannoma. 
In August 2008, 
18FDG scintigraphy showed abnormal uptake in the left jugular carotid and nodular 
pleural uptake on the right, but MIBG scintigraphy was normal. Physical examination was normal and 
did not find any catecholaminergic manifestations. 
In January 2009, FDG-TEP was carried out (33 months after the last surgery) and showed a single 
lesion, measuring 25 mm at its greatest diameter, localized in the pleural area with close contact at the 
6th rib and involved the intercostal muscle on the right. An MRI of the chest confirmed the metabolic 
imaging data, but MIBG scintigraphy was still normal. A thoracotomy was performed and permitted a 
complete macroscopic resection of the tumor. The histological findings determined that the lesion was a 
parietal and visceral pleuritic localization of the NB demonstrated with R1 resection. No complications 
were encountered during the postoperative period. The patient underwent concomitant postoperative 
radiochemotherapy with cisplatin regimen. The patient is still alive and has no new metastases more 
than 8 years after diagnosis.  
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Discussion 
Surgical resection, histology, CT, and MIBG scintigraphy are the methods of choice for 
diagnosis. 
In general, catecholamine metabolites in urine or serum, NSE, and lactate 
dehydrogenase are useful parameters for diagnosis and follow-up. However, an abnormal 
tumor marker leads to further assessment with detection of relapse or progression in only 
14% of patients [4]. For our patient, the serum dopamine level was elevated only in the 
first recurrence.  
Currently, a reported specificity of 99% and cumulative sensitivity of roughly 90% in 
paraganglioma make 
123I-MIBG the most important nuclear imaging method [5]. 
However, false negatives have been reported and may be explained by the absence of 
catecholamine reuptake and/or dedifferentiated features of malignant tumors [6, 7]. In 
our case, MIBG scintigraphy was negative in the last recurrence. 
For paraganglioma, FDG-PET diagnoses malignancy better than MIBG scintigraphy 
and reveals more metastases. However, FDG-PET has lower sensitivity and, in particular, 
lower specificity than MIBG scintigraphy for detecting paragangliomas [8, 9]. Moreover, 
there are some false positive cases with FDG-TEP, as we reported for our patient.  
The perioperative detection probe is a supplementary diagnostic tool for guiding the 
exeresis of recurrent tumors, which are sometimes difficult to access surgically. Several 
publications have reported the use of a perioperative detection probe after the injection of 
MIBG-labeled with iodine-125, or iodine-123, or 
111In-pentetrotide [10, 11]. 
Stage III and IV tumors are often initially treated with chemotherapy followed by 
tumor resection, as was done in our patient [12]. Because of a lack of experience in adults, 
the treatment followed pediatric protocols. The most frequently used cytostatic agents, 
either alone or in combination, include alkylating agents (cyclophosphamide/ifosfamide), 
platinum-based agents (cisplatin/carboplatin), etoposide, adriamycin, and vinca-
alkaloids. 
Clinical data on the survival outcomes of adult patients (defined as 20 years of age and 
older) with NB are scarce due to the rarity of the disease. Small, single institution reports 
have described worse outcomes for adults than pediatric patients [13, 14]. Data from the 
publicly accessible Surveillance Epidemiology and End Results confirm these findings, but 
there has been a trend of improved survival for the past decade, which may reflect 
advancements in treatment [15]. NB in adolescents and adults exhibits different biological 
characteristics and has a longer course than in children, with multiple recurrences and/or 
chronic persistent disease [3]. Moreover, MYCN amplification was rarely found.  
Conclusion 
Currently, there are no standard treatment guidelines for patients with adult NB. In 
patients with metastatic disease and at late stages of disease, multimodal therapy should 
include surgical resection, radiotherapy, and outpatient chemotherapy. Follow-up of 
patients with NB should include metabolic imaging studies and tumor marker 
determination. The collection and evaluation of data on adult patients with this rare 
tumor are warranted in order to optimize treatment strategies. Whether more intensive 
treatment or myeloablative therapy with stem cell support will improve the outcome of 
NB in adults is unclear.  
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